Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease

Table 1 Patient data

MS/Validation	Case	Diagnosis	M/F	Age (years)	Abeta	Tau	CERAD	PMD	APOE
MS	1	CAA type-1	F	75	A3	B3	C0^c	6:00	44
MS	2	CAA type-1	F	96	A3	B3	C0^c	4:20	43
MS	3	CAA type-1	M	68	A3^a	B1	C0^c	6:05	44
MS	4	CAA type-1	F	78	A3	NA	C0^c	4:20	44
MS	5	CAA type-1	M	81	A3	B3	C2	6:30	44
MS	6	CAA type-1	F	95	A3	B3	C2	4:35	44
MS	7	CAA type-1	M	80	A3	B3	C0^c	5:05	44
MS	8	AD	F	82	A3	B3	C3	6:00	42
MS	9	AD	F	72	A3	B3	C3	6:30	44
MS	10	AD	F	81	A3	B3	C3	6:00	33
MS	11	AD	F	73	A3	B3	C3	5:55	44
MS	12	AD	M	84	A3	B3	C3	8:05	NA
MS	13	AD	F	87	A3	B3	C3	5:45	43
MS	14	AD	F	72	A3	B3	C3	5:55	23
MS	15	Control	M	74	A0	B0	C0	8:05	33
MS	16	Control	F	80	A1	B1	C0	6:58	43
MS	17	Control	M	82	A0	B1	C0	5:10	23
MS	18	Control	M	78	A0	B1	C0	17:40	33
MS	19	Control	F	79	A0	B1	C0	18:13	33
MS	20	Control	F	81	A0	B1	C0	4:25	33
V	21	CAA type-1	F	94	A3	B3	C3	04:30	43
V	22	CAA type-1	M	74	A3	B3	C3	03:25	NA
V	23	CAA type-1	F	87	A3	B3	C3	08:00	44
V	24	CAA type-1	F	84	A3	B3	C2	04:45	NA
V	25	CAA type-1	M	88	A3	B3	C3	03:55	NA
V	26	CAA type-1	M	75	A3	B3	C0	03:15	NA
V	27	AD	M	64	A3	B3	C3	07:30	33
V	28	AD	F	81	A3	B3	C3	05:15	43
V	29	AD	F	90	A3	B3	C3	04:45	33
V	30	AD	M	65	A3	B3	C3	06:00	43
V	31	AD	F	73	A3	B3	C3	NA	NA
V	32	AD	F	90	A3	B3	C3	03:55	32
V	33	AD	M	88	A3	B3	C3	04:40	43
V	34	AD	M	74	A3	B3	C3	05:10	NA
V	35	Control	M	73	A0	B0	C0	24:45	33
V	36	Control	M	71	A0	B1	C0	07:40	33
V	37	Control	F	82	A0	B1	C0	07:00	33
V	38	Control	M	56	A0	B0	C0	09:15	43
V	39	Control	M	62	A0	B1	C0	07:20	33
V	40	Control	M	76	A0	B0	C0	06:45	33
V	41	Control	M	93	A0	B1	C0	05:05	33
V	42	Control	F	60	A0	B0	C0	08:10	32
V	43	Cotton wool	M	72	A3	B3	C0^c	05:15	43
V	44	Prp-CAA	F	57	A0	B0^b	C0	24:00	NA
V	45	CADASIL	M	73	A0	B0	C0	31:45	NA
V	46	CARASAL	F	55	A1	B1	C0	04:00	NA
V	47	Hyper tension related SVD	F	92	A1	B2	C0	07:25	NA

Alzheimer’s disease: AD, cerebral amyloid angiopathy: CAA, M: male, F: female, post mortem delay: PMD, not available/not applicable: NA, used for mass spectrometry analysis: MS, used for validation: V. (^aAβ only present as dysphoric CAA) (^bFocal tau accumulation around blood vessels with prp-amyloid deposits) (^conly dyshoric angiopathy in gallyas staining)